BY: HANNAH GANDAL

On November 9th, 2020, the American pharmaceutical corporation, Pfizer, shared that their coronavirus vaccine has been proven to be more than 90% effective. The results of the vaccine were seen to be much more successful than expected, and will be anticipated by many. 

The vaccine’s first trial consisted of 43,000 volunteers who were given two doses of the vaccine or a placebo. Of the 94 positive Covid-19 cases in the group, less than 10% were from volunteers who were given the vaccine. 

Pfizer plans on gaining emergency use authorization from the U.S. Food and Drug Administration by late November in order to get going on the manufacturing and distribution of the vaccine as soon as possible. 

The corporation has also partnered up with BioNTech, a German pharmaceutical company, to conduct another trial for the Pfizer vaccine. This trial consists of more than 43,000 participants of racially and ethnically diverse backgrounds to ensure the effectiveness of the coronavirus vaccine on people of all backgrounds. 

In an interview with STAT, the Pfizer senior vice president Matthew Gruber stated, “I’ve seen some really good things. This is extraordinary”. The company plans on testing whether or not their vaccine provides long-term protection against Covid-19 and the severity of the disease to which it protects. Gruber added, “This really bodes well for us being able to get a handle on the epidemic and get us out of this situation”. 

The Pfizer team is very optimistic and cautiously excited about this breakthrough vaccine. In a news release, Pfizer CEO Albert Bourla stated that the vaccine’s results mark “a great day for science and humanity”.